GPFA
VRDN icon

Game Plan Financial Advisors’s Viridian Therapeutics VRDN Stock Holding History

Game Plan Financial Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$228 – 423
2024
Q1 		$228 Hold
13
– – ﹤0.01% 406
2023
Q4 		$283 Buy
+13
New +$205 ﹤0.01% 405
2020
Q3 		– Sell
-4,637
Closed -$77K – 74
2020
Q2 		$77K Buy
4,637
+1,667
+56% +$18.9K 0.11% 51
2020
Q1 		$17K Sell
2,970
-933
-24% -$10.9K 0.02% 85
2019
Q4 		$28K Buy
+3,903
New +$40K 0.03% 94

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Game Plan Financial Advisors's VRDN Position: Q2 2024 in Review

Game Plan Financial Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 13 shares — an estimated $228 sold.

Game Plan Financial Advisors first reported a position in VRDN in Q4 2019 and held it in 5 quarters. The position peaked at $77K in Q2 2020. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Game Plan Financial Advisors reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Game Plan Financial Advisors sold 13 Viridian Therapeutics shares in Q2 2024, an estimated $228.
  • Game Plan Financial Advisors first reported a position in Viridian Therapeutics in Q4 2019 and held it in 5 quarters.
  • Game Plan Financial Advisors's Viridian Therapeutics position peaked at $77K in Q2 2020.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Game Plan Financial Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.